Switching at Low HIV-1 RNA into Fixed Dose Combinations: TDF/FTC/RPV is non-inferior to TDF/FTC/EFV in first-line suppressed patients living with HIV

BACKGROUND: In low- and middle-income countries (LMICs), a substantial unmet need for affordable single-tablet regimen (STR) options remains. Rilpivirine (RPV, TMC278) is formulated in a low-cost STR with tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC). OBJECTIVES: Switching at Low HIV-1...

Descripción completa

Detalles Bibliográficos
Autores principales: Munderi, Paula, Were, Edwin, Avihingsanon, Anchalee, Mbida, Pascale A.M., Mohapi, Lerato, Moussa, Samba B., Jansen, Marjolein, Bicer, Ceyhun, Mohammed, Perry, van Delft, Yvon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AOSIS 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676968/
https://www.ncbi.nlm.nih.gov/pubmed/31392036
http://dx.doi.org/10.4102/sajhivmed.v20i1.949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676968/
https://www.ncbi.nlm.nih.gov/pubmed/31392036
http://dx.doi.org/10.4102/sajhivmed.v20i1.949

Ejemplares similares